U.S. Markets closed

Alkame Holdings, Inc. Subsidiary Xtreme Technologies, Inc. Reaches Agreement for North American Representation of Its Hydro2Pro(R) Line of Pet Products by SLA Brands

LAS VEGAS, NV--(Marketwired - Apr 6, 2015) -  Alkame Holdings, Inc. ( OTCQB : ALKM ) wholly owned subsidiary Xtreme Technologies, Inc. announced that its Hydro2Pro® (www.hydro2pro.com) line of pet hydration and feeding products has selected Schiaffino, Lasky & Associates, Inc. (SLA Brands) to represent its pet product division to distributors and retailers nationwide.

"We are pleased to be working with such a well-respected group within the pet industry and look forward to SLA Brands' assistance in expanding the retail footprint of our animal products to pet retailers across the USA and Canada," states Robert K. Eakle, Alkame's CEO. "Working with SLA Brands allows Hydro2Pro® immediate access to their well established relationships with leading retailers and distributors throughout North America."

"We are looking forward to our partnership with Xtreme Technologies and leading the placement and sale of Hydro2Pro® pet products. Hydro Pet™ products will enhance the lives and health of a great variety of animal species including dogs, cats, reptiles, birds, fish and small animals," said Mike Lasky, Managing Partner, SLA Brands, Inc.

Bill Schiaffino, SLA founder and managing partner, states, "Alkame's patented water technology utilized in Hydro2Pro® pet care products is truly a quantum leap in pet hydration and health care. Xtreme Technologies has been in existence for over 17 years. For much of that time Xtreme's primary focus has been on their extensive private label business in partnership with some of the largest retailers in the country both on the human and pet side. SLA will seek to make Alkame's Hydro2Pro brand the premier line of premium hydration products in the pet channel." 

About SLA Brands, Inc.

Schiaffino & Associates was founded in 2003 to serve the pet industry in the United States and Canada. With the addition of Mike Lasky as a senior partner, Schiaffino & Associates became Schiaffino, Lasky & Associates (SLA) in 2006. SLA serves as the exclusive representative for some 30 pet products manufacturers to distributors, retail chains, catalog and Internet accounts throughout North America as well as to several major mass market chains. SLA numbers among its client companies some of the leading pet product brands in the industry. 

About Alkame Holdings, Inc.

Alkame Holdings, Inc. is a publicly traded health and wellness technology holding company with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly-owned subsidiary, Xtreme Technologies, Inc., markets and distributes micro-clustered, alkaline, antioxidant and oxygenated bottled water utilizing an exclusive patented formula and technology for the pet sector. Alkame's patented technology creates water with several unique properties which allow for greater absorption and utilization for more efficient hydration and help to achieve an optimal pH balance. The patented Alkame technology also increases the available oxygen content and absorbability which equates to more fuel for improved metabolic efficiency, boosted immune system, and improved cardio respiratory function.

For more information, visit www.alkameholdingsinc.com.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Tops Markets will achieve significant additional distribution for the Company's products, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.